FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379285958> ?p ?o ?g. }

• W4379285958 endingPage "e13027" @default.
• W4379285958 startingPage "e13027" @default.
• W4379285958 abstract "e13027 Background: The efficacy of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) and HER2 target agents combined with endocrine treatment (ET) has been demonstrated in hormone receptor (HR)-positive and HER2+ ABC, while little was known about the role of CDK4/6i in HR-/HER2+ ABC. In this prospective, multi-center, multi-cohort, phase 2 study (NCT04095390), we assessed the efficacy and safety of pyrotinib (P) and a CDK4/6i, dalpiciclib (D)-based therapy in HER2+ ABC with disparate HR statuses. Methods: HER2+ ABC females with known HR status were eligible if previously treated with trastuzumab (T). No more than one prior systemic regimen in advanced setting was allowed. Cohort A: HR+ pts received P (320 mg QD) and D (125 mg QD, 21 days on and 7 days off) combined with letrozole (2.5 mg QD). Cohort B or C: HR- pts were randomized to receive P and D combined with or without capecitabine (500 mg TID). Pts were treated until progression or unaccepted toxicity. The primary endpoint was objective response rate (ORR) per RECIST 1.1. Results: As of Jan. 16, 2023, 33 pts were enrolled. We describe pts' distribution and characteristics. 26 pts had at least one efficacy assessment, and 17 (65.4%) achieved confirmed objective responses. ORR was 66.7% (10/15), 80% (4/5), and 50% (3/6) in cohort A, B, and C, respectively. Among the ITT population, the estimated median PFS was 24.9 mo. (24.9 mo., NR, and 20.2 mo. in cohort A, B, and C, respectively). 32 (97.0%) pts experienced treatment-related adverse events (TRAEs). Grade (G) 3-4 TRAEs occurred in 81.8% of pts, and the most frequent (≥ 10%) ones were neutropenia (72.7%), leukopenia (57.6%), diarrhea (21.2%), and mucositis (12.1%). Safety profiles were similar among cohorts, except more G3-4 mucositis, hand-foot syndrome and thrombocytopenia in cohort B. Two in cohort B discontinued due to toxicity (1 rash, and 1 neutropenia). One death was reported after withdrawal and unrelated to the study. Median OS was not reached. Conclusions: Our study shows P and D combined with ET is effective in HR+/HER2+ ABC, providing a chemo-free option to these pts. In HR-/HER2+ ABC, we preliminarily observed that the addition of chemotherapy could improve effectiveness of P and D, but also increase toxicities. Due to the limited sample, the findings need further confirmation. Clinical trial information: NCT04095390 . [Table: see text]" @default.
• W4379285958 created "2023-06-05" @default.
• W4379285958 creator A5005974424 @default.
• W4379285958 creator A5011669449 @default.
• W4379285958 creator A5026804113 @default.
• W4379285958 creator A5037159025 @default.
• W4379285958 creator A5049692788 @default.
• W4379285958 creator A5067755874 @default.
• W4379285958 creator A5071385861 @default.
• W4379285958 creator A5073851139 @default.
• W4379285958 date "2023-06-01" @default.
• W4379285958 modified "2023-10-13" @default.
• W4379285958 title "Preliminary analysis of pyrotinib and dalpiciclib-based therapy in HER2-positive advanced breast cancer (ABC)." @default.
• W4379285958 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e13027" @default.
• W4379285958 hasPublicationYear "2023" @default.
• W4379285958 type Work @default.
• W4379285958 citedByCount "0" @default.
• W4379285958 crossrefType "journal-article" @default.
• W4379285958 hasAuthorship W4379285958A5005974424 @default.
• W4379285958 hasAuthorship W4379285958A5011669449 @default.
• W4379285958 hasAuthorship W4379285958A5026804113 @default.
• W4379285958 hasAuthorship W4379285958A5037159025 @default.
• W4379285958 hasAuthorship W4379285958A5049692788 @default.
• W4379285958 hasAuthorship W4379285958A5067755874 @default.
• W4379285958 hasAuthorship W4379285958A5071385861 @default.
• W4379285958 hasAuthorship W4379285958A5073851139 @default.
• W4379285958 hasConcept C121608353 @default.
• W4379285958 hasConcept C126322002 @default.
• W4379285958 hasConcept C143998085 @default.
• W4379285958 hasConcept C168563851 @default.
• W4379285958 hasConcept C188816634 @default.
• W4379285958 hasConcept C203092338 @default.
• W4379285958 hasConcept C2775930923 @default.
• W4379285958 hasConcept C2777176818 @default.
• W4379285958 hasConcept C2777909004 @default.
• W4379285958 hasConcept C2778812593 @default.
• W4379285958 hasConcept C2779744173 @default.
• W4379285958 hasConcept C2779786085 @default.
• W4379285958 hasConcept C2781413609 @default.
• W4379285958 hasConcept C2908647359 @default.
• W4379285958 hasConcept C526805850 @default.
• W4379285958 hasConcept C530470458 @default.
• W4379285958 hasConcept C71924100 @default.
• W4379285958 hasConcept C72563966 @default.
• W4379285958 hasConcept C99454951 @default.
• W4379285958 hasConceptScore W4379285958C121608353 @default.
• W4379285958 hasConceptScore W4379285958C126322002 @default.
• W4379285958 hasConceptScore W4379285958C143998085 @default.
• W4379285958 hasConceptScore W4379285958C168563851 @default.
• W4379285958 hasConceptScore W4379285958C188816634 @default.
• W4379285958 hasConceptScore W4379285958C203092338 @default.
• W4379285958 hasConceptScore W4379285958C2775930923 @default.
• W4379285958 hasConceptScore W4379285958C2777176818 @default.
• W4379285958 hasConceptScore W4379285958C2777909004 @default.
• W4379285958 hasConceptScore W4379285958C2778812593 @default.
• W4379285958 hasConceptScore W4379285958C2779744173 @default.
• W4379285958 hasConceptScore W4379285958C2779786085 @default.
• W4379285958 hasConceptScore W4379285958C2781413609 @default.
• W4379285958 hasConceptScore W4379285958C2908647359 @default.
• W4379285958 hasConceptScore W4379285958C526805850 @default.
• W4379285958 hasConceptScore W4379285958C530470458 @default.
• W4379285958 hasConceptScore W4379285958C71924100 @default.
• W4379285958 hasConceptScore W4379285958C72563966 @default.
• W4379285958 hasConceptScore W4379285958C99454951 @default.
• W4379285958 hasIssue "16_suppl" @default.
• W4379285958 hasLocation W43792859581 @default.
• W4379285958 hasOpenAccess W4379285958 @default.
• W4379285958 hasPrimaryLocation W43792859581 @default.
• W4379285958 hasRelatedWork W2070897543 @default.
• W4379285958 hasRelatedWork W2593892593 @default.
• W4379285958 hasRelatedWork W2615274570 @default.
• W4379285958 hasRelatedWork W2740803632 @default.
• W4379285958 hasRelatedWork W2793093901 @default.
• W4379285958 hasRelatedWork W2801864212 @default.
• W4379285958 hasRelatedWork W4213338662 @default.
• W4379285958 hasRelatedWork W4221096781 @default.
• W4379285958 hasRelatedWork W4229042453 @default.
• W4379285958 hasRelatedWork W4242106749 @default.
• W4379285958 hasVolume "41" @default.
• W4379285958 isParatext "false" @default.
• W4379285958 isRetracted "false" @default.
• W4379285958 workType "article" @default.